ArticleRegenerative engineering and translational medicine2026
Bioprintable Janus Base Nano-Matrix for Improved Cartilage Tissue Engineering.
Article in Regenerative engineering and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Purpose: Bioprinting is an additive manufacturing technique used to print living cells within a three-dimensional scaffold that mimics natural tissue microenvironments. There are several disadvantages to using hydrogel-based biomaterials for bioprinting including limited cell adhesion and functionality. To address this, we have developed a library of Janus base Nano-Matrices (JBNms) which are novel nanoscale scaffolds self-assembled from DNA-inspired Janus base nanotubes (JBNts) and ECM molecules. In this study, JBNms are incorporated in bioprinting by printing a cartilage-specific JBNm with human mesenchymal stem cells (hMSCs) into a 3D alginate scaffold to selectively improve chondro-lineage cell adhesion and differentiation. Methods: Human mesenchymal stem cells (hMSCs) were combined with a cartilage-specific JBNm and printed within an alginate-based bioink. They were maintained in chondrogenic media and were characterized at 7 and 28 days. Reverse transcription quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) and histological staining were used to determine the presence of cartilage-specific genes and proteins. Results: The bioprinted structures with the cartilage-specific JBNm showed significantly greater expression of chondrogenic-related marker genes and glycosaminoglycan (GAG) expression after 28 days compared to the negative control group, indicating successful chondrogenesis. The cells were viable within the structures and showed significant proliferation after 28 days. Conclusion: Cartilage-specific JBNm scaffolds successfully promote enhanced hMSC adhesion, growth, and chondrogenic differentiation within bioprinted constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.